Effects of dexmedetomidine on septic shock ICU patients

Phase 3

• Conditions: Septic shock.; Severe sepsis with septic shock; R65.21

• Registration Number: IRCT20181104041551N2
• Lead Sponsor: Mazandaran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 March 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

Patients with septic shock over 18 years old

Exclusion Criteria

History of beta-blockers using
Heart block or sick sinus syndrome
Norepinephrine greater than 10 mcg/kg/min

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum level of Inflammatory factor IL-1. Timepoint: Before the use of dexmedetomidine and after 24 hours. Method of measurement: ELISA test.;Serum level of Inflammatory factor IL-6. Timepoint: Before the use of dexmedetomidine and after 24 hours. Method of measurement: ELISA test.;Serum level of Inflammatory factor TNF-a. Timepoint: Before the use of dexmedetomidine and after 24 hours. Method of measurement: ELISA test.

Secondary Outcome Measures

Name	Time	Method
Investigation of the sedative effects of dexmedetomidine. Timepoint: Baseline and after 24 hours. Method of measurement: Richmond agitation-sedation scale.;Changing norepinephrine dose of. Timepoint: Baseline and after 24 hours. Method of measurement: Clinical observation.;Changing in Sofa score. Timepoint: Baseline and after 24 hours. Method of measurement: checklist.